Drug Use Evaluation of Tenofovir/Lamivudine/Dolutegravir (TLD) Fixed-Dose Combination for Initiation and Transition Among HIV-Infected Individuals Attending Lumame Primary Hospital, North West Ethiopia

References

• World Health Organization. Updated Recommendations on First-Line and Second-Line Antiretroviral Regimens and Post-Exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV: Interim Guidelines: Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. World Health Organization; 2018.
   Google Scholar
• Umar D, Waziri B, Ndagi U, Mohammed S, Usman N, Abubakar-Muhammad H. Impact of tenofovir/lamivudine/dolutegravir (Tld) on the health-related quality of life and clinical outcomes of HIV/AIDS patients at a tertiary health facility in Niger State. 2020. doi:10.21203/rs.3.rs-127277/v1Corpus
   Google Scholar
• Dyer M, Kerr C, Fine SM, et al. Comprehensive primary care for adults with HIV [internet]. Baltimore (MD): Johns Hopkins University; 2022 Dec. Available from: https://www.ncbi.nlm.nih.gov/books/NBK567851/
   Google Scholar
• Federal democratic republic of Ethiopia ministry of health NCGfCHP. Care Treat. 2018.
   Google Scholar
• Federal democratic republic of Ethiopia ministry of health, national consolidated guidelines for comprehensive HIV prevention. Care Treat. 2018.
   Google Scholar
• Federal democratic republic of Ethiopia ministry of health, implementation manual for DTG rollout and ART optimization in Ethiopia. 2019.
   Google Scholar
• World Health Organization. Transition to New Antiretroviral Drugs in HIV Programmes: Clinical and Programmatic Considerations. World Health Organization; 2017.
   Google Scholar
• Katbi M, Adeoye O, Adedoyin A, Faturiyele I, Adegboye A, Bello M. Virologic response among key populations living with HIV following a switch to dolutegravir-based regimen in Southern Nigeria. Int J Virol AIDS. 2020;7:069.
   Google Scholar
• Paul NI, Ugwu RO. Dolutegravir (DTG) based fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD) and viral load suppression in children in port harcourt, Nigeria. J Sci Res Rep. 2020;52–59. doi:10.9734/jsrr/2020/v26i230224
   Google Scholar
• Sohler N, Slawek D, Earnshaw V, et al. Drug use and HIV medication adherence in people living with HIV. Subs abu. 2021;42(3):310–316. doi:10.1080/08897077.2019.1706695
   PubMed Web of Science ®Google Scholar
• Mekonnen BD, Ayalew MZ, Tegegn AA. Rational drug use evaluation based on World Health Organization core drug use indicators in Ethiopia: a systematic review. Drug Healthcare Patient Safe. 2021;13:159–170. doi:10.2147/DHPS.S311926
   PubMed Web of Science ®Google Scholar
• Desai M, Iyer G, Dikshit RK. Antiretroviral drugs: critical issues and recent advances. Indian J Pharmacol. 2012;44(3):288–298. doi:10.4103/0253-7613.96296
   PubMed Web of Science ®Google Scholar
• Gupta RK, Gregson J, Parkin N, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18(3):346–355. doi:10.1016/S1473-3099(17)30702-8
   PubMed Web of Science ®Google Scholar
• Tassew SG, Abraha HN, Gidey K, Gebre AK. Assessment of drug use pattern using WHO core drug use indicators in selected general hospitals: a cross-sectional study in Tigray region, Ethiopia. BMJ open. 2021;11(10):e045805. doi:10.1136/bmjopen-2020-045805
   PubMed Web of Science ®Google Scholar
• Aynalem GA, Bekele TA, Alemayehu FA. Drug use evaluation of vancomycin at medical ward of yekatit 12, hospital medical college, addis ababa, Ethiopia, 2018. Int J. 2020;6(10):381.
   Google Scholar
• Gangwar R, Kumar A, Zargar AA, Sharma A, Kumar R. The role of drug utilization evaluation in medical sciences. Global Health J. 2023;7(1):3–8. doi:10.1016/j.glohj.2023.02.002
   Google Scholar
• Sart AA, Usan S. Perform an effective medication-use evaluation: December 2017. Phar Purch Prod Magazi. 14(12):1.
   Google Scholar
• Jagarlamudi A, Vishali A, Mounika I. Drug Utilization Evaluation of Metronidazole at a Tertiary Care Center in Hyderabad, India. J Drug Delivery Ther. 2019;9(3):272–278.
   Google Scholar
• World Health Organization. Drug and Therapeutics Committees: A Practical Guide. World Health Organization; 2003.
   Google Scholar
• Joint Commission on Accreditation of Healthcare Organizations. Approved: the Joint Commission’s hospital performance measurement implementation plan through 2008. Jt Comm Perspect. 2007 Mar;27(3):1, 3–5. PMID: 17416141.
   Google Scholar
• Holloway K, Green T. Drug and Therapeutics Committees a Practical Guide. France: World Health Organization (WHO); 2003.
   Google Scholar
• Mousavi S, Behi M, Taghavi MR, Ahmadvand A, Ziaie S, Moradi M. Drug utilization evaluation of imipenem and intravenous ciprofloxacin in a teaching hospital. Iran J Pharm Res Winter. 2013;12(Suppl).161–7. PMID: 24250684; PMCID: PMC3813373.
   PubMedGoogle Scholar
• Kouamou V, Machekano R, Mapangisana T, et al. Tenofovir, lamivudine, and dolutegravir among rural adolescents in Zimbabwe: a cautionary tale. AIDS Res Hum Retro. 2022;38(10):774–778. doi:10.1089/aid.2021.0140
   PubMed Web of Science ®Google Scholar
• Mir SA, Muzamil F, Bhat M, Amin A, Shakeel D. Assessment of medication adherence among patients with chronic diseases: a descriptive cross-sectional study. Int J Basic Clin Pharmacol. 2018;8(1):115. doi:10.18203/2319-2003.ijbcp20185168
   Google Scholar
• Lemay J, Waheedi M, Al-Sharqawi S, Bayoud T. Medication adherence in chronic illness: do beliefs about medications play a role? Patient Prefer Adher. 2018;12:1687. doi:10.2147/PPA.S169236
   PubMed Web of Science ®Google Scholar
• Back D, Marzolini C, Gibbons S, et al. HIV Drug Interactions. Liverpool: University of Liverpool; 2018.
   Google Scholar
• Considerations for the Introduction of TLD in national programs: PEPFAR guidance on developing clinical and programmatic recommendations. 2018.
   Google Scholar
• Zamora, Stajduhar KI, Mollison A, Giesbrecht M, et al. Dolutegravir and lamivudine combination for the treatment of HIV-1 infection HIV/AIDS. Res Pallia Care. 2019;18(1):11. doi:10.1186/s12904-019-0396-7.
   Google Scholar
• Walimbwa SI, Lamorde M, Waitt C, et al. Drug interactions between dolutegravir and artemether-lumefantrine or artesunate-amodiaquine. Antimi Agen Chemo. 2019;63(2). doi:10.1128/AAC.01310-18.
   Web of Science ®Google Scholar
• World Health Organization. Policy Brief: Update of Recommendations on First-and Second-Line Antiretroviral Regimens. World Health Organization; 2019.
   Google Scholar
• Lu L, Li X, Liu X, et al. Comparison of renal function biomarkers of serum creatinine and cystatin c in HIV-infected people on dolutegravir-containing therapy. Infect Drug Resist. 2022;15:1695–1706. doi:10.2147/IDR.S347054
   PubMed Web of Science ®Google Scholar
• Mabirizi D, Phulu B, Churfo W, et al. Implementing an integrated pharmaceutical management information system for antiretrovirals and other medicines: lessons from Namibia. Global Health. 2018;6(4):723–735. doi:10.9745/GHSP-D-18-00157
   Google Scholar